嚢胞性線維症治療薬の市場規模、シェア、成長分析：薬剤クラス別、投与経路別、流通チャネル別、地域別 - 産業予測 2025～2032年

嚢胞性線維症治療薬市場規模は2023年に65億米ドルと評価され、2024年の74億2,000万米ドルから2032年には213億1,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは14.1%で成長する見通しです。

嚢胞性線維症（CF）治療薬市場は、CFの有病率の上昇と治療率の増加を原動力に大きく成長する見通しです。官民両部門からの研究開発への資金調達の強化や、強力な非営利イニシアティブが市場拡大をさらに後押ししています。患者数が年々増加しているため、CFTR調節薬、粘液溶解薬、抗生物質など既存の薬剤クラスの利用が増加しており、効果的な治療法に対する需要が高まっています。さらに、主要製薬企業による革新的な治療薬のパイプラインの増加や、顧客層の拡大を目指した研究が進行していることも、市場ダイナミクスに寄与しています。CFの研究開発を支援するいくつかの慈善団体の積極的な役割も、市場の成長を促進する重要な要因です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• 技術分析

嚢胞性線維症治療薬市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 抗感染薬
• CFTRモジュレーター
• 膵臓酵素サプリメント
• 粘液溶解薬
• 気管支拡張薬

嚢胞性線維症治療薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 吸入

嚢胞性線維症治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

嚢胞性線維症治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Vertex Pharmaceuticals（USA）
• AbbVie（USA）
• Gilead Sciences（USA）
• Roche（Switzerland）
• Teva Pharmaceutical Industries（Israel）
• Mylan（now Viatris）（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• Alaxia.
• Allergan（now part of AbbVie）（Ireland）
• Beyond Air Inc.（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co. Inc.（USA）
• Alcresta Therapeutics Inc.（USA）
• Chiesi（Italy）
• Nestle HealthScience（Switzerland）
• Pharmaxis Ltd.（Australia）
• PTC Therapeutics, Inc.（USA）
• Insmed, Inc.（USA）
• Grifols S.A.（Spain）

結論と提言

Cystic Fibrosis Therapeutics Market size was valued at USD 6.5 billion in 2023 and is poised to grow from USD 7.42 billion in 2024 to USD 21.31 billion by 2032, growing at a CAGR of 14.1% during the forecast period (2025-2032).

The cystic fibrosis (CF) therapeutics market is poised for significant growth driven by the rising prevalence of CF and an increase in treatment rates. Enhanced funding for research and development from both public and private sectors, along with robust nonprofit initiatives, is further propelling market expansion. The demand for effective therapies is increasing due to a year-on-year rise in patient numbers, leading to greater utilization of existing drug classes, including CFTR modulators, mucolytics, and antibiotics. Additionally, a growing pipeline of innovative therapy compositions from leading pharmaceutical companies and ongoing studies aimed at broadening their customer base will contribute to market dynamics. The active role of several charitable organizations in supporting CF research and development is also a crucial factor in fostering market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cystic Fibrosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cystic Fibrosis Therapeutics Market Segments Analysis

Global Cystic Fibrosis Therapeutics Market is segmented by Drug Class, Route Of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-infectives, CFTR Modulators, PancreaticenzymeSupplements, Mucolytics and Bronchodilators. Based on Route Of Administration, the market is segmented into Oral and Inhaled. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cystic Fibrosis Therapeutics Market

The cystic fibrosis therapeutics market is predominantly driven by the rising incidence of cystic fibrosis, a genetic disorder that significantly impacts the respiratory, digestive, and reproductive systems. As this debilitating condition remains incurable, patients necessitate continuous treatment throughout their lives, which in turn fuels the demand for effective cystic fibrosis therapeutics. As more individuals are diagnosed and require ongoing care, the market is expected to see substantial growth, underscoring the critical need for innovative treatments and supportive therapies to enhance the quality of life for those affected by this chronic illness.

Restraints in the Cystic Fibrosis Therapeutics Market

The elevated prices associated with cystic fibrosis treatments, especially innovative targeted therapies, pose a significant challenge to patient access. This situation raises crucial concerns regarding the affordability of these essential medications and their influence on healthcare systems. Many patients are unable to obtain necessary treatments due to the financial burden, which can lead to potential disparities in healthcare outcomes. As a result, these high costs not only affect individual patients but also strain the resources of healthcare providers and insurers, ultimately complicating the management of cystic fibrosis and limiting the overall efficacy of available therapies.

Market Trends of the Cystic Fibrosis Therapeutics Market

The cystic fibrosis therapeutics market is witnessing a significant shift towards personalized medicine, driven by advancements in genomic research and a deeper understanding of the disease's genetic underpinnings. As more targeted therapies emerge that cater to specific mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, patients are increasingly seeking tailored treatment options that provide enhanced efficacy and improved outcomes. This trend is anticipated to escalate, encouraging pharmaceutical companies to invest in innovative research and development, ultimately transforming cystic fibrosis management. Consequently, a robust growth trajectory is expected in the personalized medicines segment, solidifying its prominence in the evolving therapeutics landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis

Global Cystic Fibrosis Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-infectives
• CFTR Modulators
• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators

Global Cystic Fibrosis Therapeutics Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Inhaled

Global Cystic Fibrosis Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cystic Fibrosis Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Route Of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Route Of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route Of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route Of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route Of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (now Viatris) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alaxia.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (now part of AbbVie) (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beyond Air Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcresta Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle HealthScience (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaxis Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insmed, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations